About this event

American Society of Human Genetics (ASHG) — Event Deep Research Description

This page provides an end-to-end research view of the American Society of Human Genetics (ASHG) event for deep B2B prospecting and audience-list research. We focus on buyer/attendee roles, geographic reach, audience composition, engagement themes, estimated scale, and recommended buyer types mapped to our client’s needs (based on the client product fit).

Event basics (from provided website content)

• Event title: American Society of Human Genetics (ASHG)
• Dates: (not provided in the provided source text)
• Venue: (not provided in the provided source text)
• City & Country: (not provided in the provided source text)
• Official event page URL used: https://meetings.ashg.org/event/EVEEGOIQACFJJ/home/

Note: The official text provided in the prompt did not include the meeting dates/venue/city/country details. Per instructions, we do not invent or contradict those facts; therefore we leave these fields as “not provided”.

---

1) Who attends (BUYERS / ATTENDEES)

ASHG is a research- and clinical-innovation heavy scientific meeting where the strongest “buyer” overlap usually appears in organizations that translate genetics into diagnostics, therapeutics, research tools, data platforms, and clinical programs. While the visible attendee population includes researchers and clinicians, the monetizable layer for prospecting is commonly found in the professional decision-making and investment roles around:

Primary attendee groups we see at ASHG

• Academic & research buyers (high-intent for solutions): Principal investigators, lab directors, department heads, genomics research program leads, translational research leaders, and research administration stakeholders.
• Clinical and medical genetics stakeholders: Medical directors, clinical lab directors, translational medicine physicians, genetic counselors (often as influencers), and clinical operations leaders tied to diagnostic workflows.
• Industry buyers (most relevant for sponsored programs, pilots, and partnerships): Business development leaders, strategic partnerships managers, market access leaders, clinical trial operations leads, translational science leaders, medical affairs leaders, and R&D commercialization stakeholders.
• Technology and platform buyers: Heads of product, solution architecture leads, data/analytics leadership, informatics directors, and workflow/implementation leaders for genomics platforms.
• Diagnostics, sequencing, and tools buyers: Laboratory operations leaders, clinical development leaders, assay validation leads, and product management leaders for lab and clinical-grade workflows.
• Regulatory, quality, and compliance-adjacent roles: Quality leaders, regulatory affairs leads, and validation stakeholders (particularly if the client product supports compliance-heavy use cases).

In short: ASHG is not just “conference attendees.” It is a concentrated concentration of people deciding what gets funded, what gets deployed in labs/clinics, what tools get selected for trials, and what partnerships move forward in genetics.

Best “buyer” personas to target

• Director/VP of Genomics Research or Translational Research
• Head of Clinical Genetics / Clinical Lab Director
• Medical Affairs Director / Clinical Science Lead
• Business Development Director / Partnerships Lead (Diagnostics, Genomics, Bioinformatics)
• Product Director / Product Management Lead (Genomics platforms, sequencing workflows, data tools)
• Head of Informatics / Director of Data Science (Genetics & Omics analytics)
• Regulatory Affairs Director (if the solution supports validated clinical workflows)
• Research Administration / Grants & Research Program Managers (academic buyer influence)

---

2) Where the show is happening + attendee geographic origin

Venue details: not provided in the supplied source text, so we cannot state the city/country without risking inaccuracy.

Attendee geographic origin (reliable research expectation for ASHG-type meetings): ASHG typically draws a strong international mix because genetics research is globally networked and because many multinational biotech/pharma and global research institutions participate. The audience commonly includes:

• United States-based attendees: very strong presence across academic medical centers, national research institutions, and U.S.-headquartered biotech and diagnostics organizations.
• Europe: strong attendance from genomics research networks, hospitals, and biotech companies.
• Asia-Pacific: increasing participation driven by sequencing scale-up, precision medicine programs, and multinational clinical trial pipelines.
• Canada and LATAM: meaningful participation through collaborations and clinical research programs.

For list-building purposes, the most effective geographic targeting is usually: North America first (especially U.S.), then Europe, then APAC, with secondary attention to globally distributed biotech/diagnostics headquarters and regional research clusters.

---

3) Audience reach (Local / National / Global)

ASHG’s reach is best characterized as global. Even if the in-person location is city-based, the attendee and exhibitor ecosystem is international by design: multinational companies, international academic centers, and global research collaborations are typically well represented.

• Local: the immediate metro area participates primarily as an access point, but it is not the defining audience.
• National: for the host country, it is a top-tier national meeting for genetics and genomics.
• Global: the core value is cross-border networking across translational medicine, diagnostics, platforms, and research.

---

4) Sample buyer company names (BUYERS ONLY) + Websites

Below are examples of buyer-fit companies that are the most plausible targets when the goal is to connect with decision makers in human genetics research, translational medicine, genomics analytics, diagnostics, sequencing workflows, and related tools. These are included as “buyer targets” rather than generic exhibitors.

Priority	Company	Website	Best Title to Target	Why This is a Good Buyer Fit
1	Illumina	https://www.illumina.com	Director, Clinical Genomics Product / Product Management Lead	Genomics sequencing platform leader; strong alignment with clinical genomics workflows, research tool adoption, and trial enablement.
2	Thermo Fisher Scientific	https://www.thermofisher.com	VP, Genomics Solutions / Director, Clinical Research Services	End-to-end lab and analysis ecosystem; buyers often attend to evaluate platforms, workflows, and program partnerships.
3	Roche (Diagnostics)	https://diagnostics.roche.com	Director, Companion Diagnostics / Head of Clinical Evidence	Direct fit with genetics-driven diagnostics and evidence generation; strong relevance for clinical and medical genetics stakeholders.
4	QIAGEN	https://www.qiagen.com	Director, Translational Genomics / Product Strategy Lead	Workflow and sample-to-answer genomics and molecular solutions; buyers align with research scale and clinical enablement.
5	Guardant Health	https://www.guardanthealth.com	Medical Affairs Director / Head of Clinical Development	Genetics-informed oncology and testing; strong engagement with clinical trial operations and evidence stakeholders.
6	Foundation Medicine	https://www.foundationmedicine.com	Director, Clinical Partnerships / Medical Director	Precision medicine and genomic testing; relevant buyer for partnerships, clinical validation, and research collaborations.
7	Labcorp	https://www.labcorp.com	Clinical Lab Director / Director, Molecular Diagnostics	Diagnostics and clinical lab operations; strong alignment with genetics testing workflows and adoption decisions.
8	Myriad Genetics	https://myriad.com	Director, Clinical Strategy / Vice President, Clinical Affairs	Genetic testing and clinical evidence; buyer-fit roles focus on clinical deployment and partnership expansion.
9	Personalis	https://www.personalis.com	Director, Translational Science / VP, Clinical Development	Genomics-driven precision medicine; aligns strongly with human genetics research translation and evidence building.
10	Genomind (if applicable for genetic services ecosystem)	https://www.genomind.com	Director, Clinical Program Management	Genetics-based clinical decision support ecosystem; buyer relevance depends on current portfolio and participation focus.
11	Tempus	https://www.tempus.com	Director, Data Science Partnerships / Head of Clinical Evidence	Genomics and data platform; buyers often target precision medicine and real-world evidence opportunities.
12	GRAIL	https://www.grail.com	Clinical Partnerships Director / Head of Clinical Evidence	Multi-cancer early detection and genomics; strong alignment with clinical evidence, trial partnerships, and implementation buy-in.
13	Sema4	https://www.sema4.com	Director, Clinical Genetics / Business Development Lead	Clinical genetics testing services; relevant for market expansion, referral network growth, and clinical workflow adoption.
14	Cerba Research (where applicable)	https://www.cerba.com	Head of Genomics Operations / Director, Clinical Laboratory Services	Clinical research lab services; buyers align with study execution, validation workflows, and multi-site partnerships.
15	Syapse	https://www.syapse.com	Head of Healthcare Data Partnerships / Director, Clinical Informatics	Genetics and research collaboration infrastructure; strong alignment with informatics buyers and program scaling.
16	Bio-Rad Laboratories	https://www.bio-rad.com	Director, Genomics & Research Solutions / Product Marketing Lead	Molecular biology and genetics research tools; buyers align with lab automation and genomics workflow improvements.
17	SOPHiA GENETICS	https://sophiagenetics.com	Director, Clinical Informatics / Head of Genomics Software Solutions	Genetics data interpretation and software; strong fit for informatics and clinical evidence stakeholders.
18	Twist Bioscience	https://twistbioscience.com	Director, Research Partnerships / Product Strategy Lead	Synthetic DNA and genomics enablement; buyer relevance for research scale, assays, and translational projects.
19	OM1	https://om1.com	Director, Scientific Partnerships / Head of Genomics Data Products	Clinical and scientific evidence data platform; buyers align with trial matching, cohort analysis, and data partnerships.
20	IQVIA	https://www.iqvia.com	Director, Real-World Evidence / Head of Clinical Solutions	Evidence generation, analytics, and clinical operations support; good buyer-fit for genetics-driven programs and RWE needs.

Top “send-first” buyer targets (shortlist we recommend): Illumina, Thermo Fisher Scientific, Roche (Diagnostics), QIAGEN, Labcorp. These typically map well to sequencing/diagnostics platforms, clinical lab workflows, and evidence-driven genetics programs.

---

5) Job profiles, industries & event type

5A) Best job profiles to target

• Clinical and diagnostic decision makers: Clinical Lab Director, Director of Molecular Diagnostics, Medical Director, Companion Diagnostics Lead
• Translational research and evidence builders: Director, Translational Research; Head of Clinical Evidence; VP Clinical Development
• Informatics and genomics platform stakeholders: Director of Informatics, Head of Data Science, Product Director (Genomics Software)
• Partnership and growth buyers: Director of Business Development, Strategic Partnerships Lead, Alliance Manager
• Regulatory/compliance & validation stakeholders (if relevant to the product): Regulatory Affairs Director, Validation Lead, Quality Systems Manager
• Program operations (if relevant to study execution): Clinical Trial Operations Lead, Study Implementation Manager
• Academic research leadership (influencers and buyers via collaboration): PI, Lab Director, Department Chair, Research Administration Manager

5B) Best-fit event type

• Scientific conference centered on human genetics and genomics
• Translational medicine and clinical innovation event
• Industry technology adoption and partnership showcase
• Research tool + data platform ecosystem convergence

5C) Best-fit industries mapped to the provided industry list

We recommend using (and validating) these “industry filters” from the provided list as the closest conceptual matches:

• Pharmaceuticals
• Medical Devices
• Hospital & Health Care
• Biotechnology
• Research
• Information Technology & Services
• Information Services
• Computer Software
• Market Research (for insights/R&D evidence contexts)
• Professional Training & Coaching (only if the client sells training/education around genomics workflows)

---

6) Estimated attendance (expected total footfall)

Because the provided source text did not include attendance figures, we cannot reliably quote a specific total footfall number. For robust research execution, we recommend pulling expected attendance from the event’s official attendee-at-a-glance or exhibitor prospectus section.

In the meantime, for buyer-list planning, we treat ASHG as a large, high-density scientific meeting with a strong presence of: clinical genetics decision-makers, genomics platform teams, and strategic partnership stakeholders across diagnostics and life sciences.

Action we recommend: If we receive the ASHG meeting edition you are targeting (year) or a link that includes “attendance” or “exhibitor prospectus,” we can fill the exact estimated attendance number in this section.

---

7) Key focus areas & buyer engagement

ASHG typically concentrates on advancing human genetics knowledge and accelerating translation into clinical and therapeutic impact. That translates into buyer engagement around these practical themes:

Key focus areas we expect to drive sponsor/exhibitor conversations

• Genomic medicine and clinical translation: moving genetic insights into diagnostics, risk assessment, and patient care pathways
• Sequencing and lab workflow innovation: sample-to-answer performance, validation, reproducibility, and clinical deployment
• Bioinformatics and interpretation: variant interpretation, data harmonization, and evidence building
• Precision medicine and biomarker enablement: identifying actionable targets and improving stratification
• Rare disease discovery: diagnostic yield improvements and research-scale data collection
• Clinical trials and evidence generation: cohort identification, endpoints, and real-world evidence needs
• Collaboration and partnership building: multi-institution consortia and industry-academic partnerships

Buyer engagement angles that typically work well

• “Enable clinical translation” messaging for diagnostics, workflow, and evidence-driven buyers
• “Reduce turnaround time / improve validation” messaging for lab and operations leadership
• “Scale interpretation and data integration” messaging for informatics buyers
• “Strengthen research-to-trial pipeline” messaging for translational medicine and CRO/RE&RWE teams
• “Partnership-first outreach” messaging for alliance and business development stakeholders

---

8) Client product review + best buyers fit (needs your client website)

We can narrow this from “generic ASHG buyer types” into a precise shortlist of best-fit buyers for your product—but we need your client product details. Please share:

• Your client website URL (the official product/service page)
• What the client sells (1–2 sentences)
• Who the buyer is (e.g., clinical lab directors, sequencing platform teams, biotech BD, genomics informatics teams)
• Target geography (if any)

Once we review the client website, we will:

• Select the best-fit company segments from the ASHG ecosystem (diagnostics, sequencing, informatics, clinical evidence, etc.)
• Map your offering to the most relevant job profiles and industries from the provided industry list
• Produce a refined “best buyers to target first” table (15–20 rows) matched to your exact requirement
• Recommend the most effective outreach angles by buyer persona

For now (provisional guidance before we see your website): If your client product is in genomics sequencing, lab workflows, diagnostics, or clinical-grade testing support, the best buyer fits are typically: Clinical Lab Directors, Molecular Diagnostics Directors, Companion Diagnostics Leads, Clinical Evidence leaders, and Translational Science leaders. If the client product is in bioinformatics/data interpretation, the best buyer fits are Informatics Directors, Data Science Leads, and Genomics Software Product leaders.

---

9) Final recommendation (who is most worth targeting and why)

Even without the exact dates/venue/attendance from the provided source text, ASHG’s attendee ecosystem is strong for B2B prospecting because:

• It concentrates decision-making around genetics translation, diagnostics, sequencing, and informatics
• It brings both academic and industry stakeholders together in a single high-density venue
• It supports high-intent networking for partnerships, clinical evidence, research enablement, and platform selection

Primary best-fit buyer segments we recommend targeting at ASHG:

• Diagnostics & clinical genetics leaders (labs, medical directors, companion diagnostics)
• Genomics platform decision makers (sequencing, workflow, lab technology, software)
• Translational and clinical evidence buyers (clinical development, medical affairs, clinical evidence)
• Business development & partnership leaders (alliance building and collaboration programs)

Next step to finalize buyer selection for your specific client: Send us the client website URL so we can match the product to the most relevant ASHG buyer personas and produce a tighter, higher-quality buyer shortlist.